Work

A Phase I Study of FT819, a First-of-Kind, Off-the-Shelf, iPSC-Derived TCR-Less CD19 CAR T Cell Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

Year: 2020

Type: article

Source: Blood

DOI: 10.1182/blood-2020-142423

Authors: Jae H. Park, Nitin Jain, Andy Chen, Joseph P. McGuirk, Monica Diaz, Bahram Valamehr, Yu-Waye Chu, Januario E. Castro

Institutions: Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Oregon Health & Science University, Oregon Health and Science University Hospital, University of Kansas Medical Center, Fate Therapeutics (United States), Mayo Clinic Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3097052250

FWCI: 0.635

Cites:

Cited by: 16

Related to: 10